GemerSitaTM : Place in the management of type 2 diabetes
A practical advice on the optimal use of the fixed-dose drug combination of Glimepiride + Metformin + Sitagliptin in the Indian scenario
GemerSitaTM : Managing uncontrolled type 2 diabetes in elderly, obese, retired pensioner – A typical patient from East India
Insights into up-titration of therapy to the fixed-dose drug combination of Glimepiride + Metformin + Sitagliptin in elderly, obese, type 2 diabetic patient on a high-glycemic index diet, uncontrolled on current therapy with Glimepiride and Metformin and experiencing occasional symptoms of hypoglycemia.
GemerSitaTM : Managing type 2 diabetes in a young newly-diagnosed patient uncontrolled on sitagliptin/metformin dual drug combination – A typical patient from West India.
A practical advice on the optimal use of the fixed-dose drug combination of Glimepiride + Metformin + Sitagliptin in newly diagnosed patient with type 2 diabetes not controlled with two-drug combination.
GemerSitaTM : Managing type 2 diabetes in middle-aged patient consuming high-carbohydrate diet, uncontrolled on glimepiride/metformin combination and experiencing occasional hypoglycaemic episodes – A typical patient from West India.
Optimal management using the triple drug combination of Glimepiride + Metformin + Sitagliptin in a case of long-standing type 2 diabetes not controlled with two-drug combination, without adverse effects like hypoglycaemia or weight gain and with good adherence to treatment.
GemerSitaTM : Appraising the Therapeutic Rationale and Clinical Role of Triple Drug Therapy in the Management of T2DM in Indian Settings.
In the face of practical challenges in Indian settings such as high rates of suboptimal glycemic control, patient non-adherence to therapy, and the issue of dose-escalation with sulfonylureas, the triple drug combination of Glimepiride + Metformin + Sitagliptin offers an effective and well-tolerated therapy for patients with type 2 diabetes who are newly diagnosed and have an HbA1c >8% and those not at control with dual drug therapy.
GemerSitaTM : Managing uncontrolled type 2 diabetes in a middle-aged woman on high carbohydrate diet – A typical patient from East India
This middle-aged, obese woman, indulging in high-carbohydrate diet and leading a sedentary life required counseling on correct diet and physical activity. Initiating therapy with triple drug combination of low-dose Glimepiride with Metformin and Sitagliptin resulted in good glycemic control without causing weight gain.
GemerSitaTM : Managing type 2 diabetes in a young man with uncontrolled diabetes, works night shifts and has unhealthy lifestyle and compliance issues to therapy – A typical patient from North India
This young man with no ASCVD risk factors required comprehensive management including correction of unhealthy diet, increasing physical activity and initiating therapy with triple drug combination of low-dose Glimepiride with Metformin and Sitagliptin. The patient showed good glycemic control and there were no adverse effects or adherence issues to treatment.
GemerSitaTM : Managing type 2 diabetes in a perimenopausal woman from a lower middle-class family and suboptimal glycemic control – A typical patient from South India
This perimenopausal woman with no ASCVD risk factors but gaining weight recently required a comprehensive approach with correction of lifestyle issues, reassurance about affordability of treatment. Treatment with triple drug combination of low-dose Glimepiride, Sitagliptin, and Metformin was initiated, resulting in good glycemic control and modest weight reduction. No adverse events or adherence issues were noted.
GemerSitaTM : Managing type 2 diabetes in a middle-aged obese North Indian woman with suboptimal glycemic control
This 45-year-old obese woman with uncontrolled type 2 diabetes has no ASCVD risk factors but indulges in a fat-rich low-fibre food and leads a sedentary life. She was managed with lifestyle counseling, and pharmacotherapy up-titrated from glimepiride/metformin dual therapy to a fixed-dose triple drug combination of low-dose Glimepiride, Sitagliptin, and Metformin. She responded well with good glycemic control and modest weight loss after 12 weeks of therapy.
